Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Amgen, Cytokinetics Checked With Payers Before Taking Omecamtiv Into Phase III

Executive Summary

Partnered on chronic heart failure drug omecamtiv mecarbil, Amgen and Cytokinetics took months to design a Phase III trial that would address the needs and concerns of both payers and clinicians.


Related Content

Novartis Woos Payers With Data Showing Entresto Earns Its Keep
Cytokinetics Seeks ALS Success By Focusing On Lung Function
Does Novartis Need A Big Immuno-Oncology Deal? Jimenez Says No
Cytokinetics Awaits Amgen's Phase III Plan After Phase II Heart Drug Success
Novartis' Entresto: Slow Uptake Expected Following Fast FDA Approval
Amgen, Cytokinetics' heart drug misses goal in Phase II study


Related Companies

Related Deals